China halts import and sale of Sun Pharma rivastigmine capsules
Regulator bans drug import, sale and use over manufacturing deficiencies
Change
China prohibited import, sale, and use of Sun Pharma’s rivastigmine capsules following inspection failures.
Why it matters
The regulator imposed a full ban on the product after identifying manufacturing and quality-control deficiencies. The restriction applies across importation, distribution, and clinical use.
Implications
- — Pharmaceutical companies must ensure compliance with manufacturing standards — failures risk product bans
- — Healthcare providers must stop use of affected products — non-compliance risks regulatory action
Full decision brief
See the decision layer
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jun
Source